METHODOLOGY FOR DEVELOPING DRUGS IN ALZHE IMER-DISEASE

Authors
DUBOIS B STEHLE B LEHNER JP DEROUESNE C BOURIN M LAMOUR Y BLIN O JOURDAIN G ALPEROVITCH A ALLARD M BILLARDON M CATTELIN F CHILDS M DELACOURTE M DELALLEAU B DIGIAMBERARDINO L EMRE M GENTHON R GONI S JAFFARD R LACOMBLEZ L LEBERT F LEGER JM MAHIEUX F MICHEL B PARTIOT A PASQUIER F PAUL HPS PUECH A REIGNEAU O RENAULT S SCHLENCK A
Citation
B. Dubois et al., METHODOLOGY FOR DEVELOPING DRUGS IN ALZHE IMER-DISEASE, Therapie, 51(4), 1996, pp. 444-448
Citations number
7
Categorie Soggetti
Pharmacology & Pharmacy
Journal title
Therapie → ACNP
ISSN journal
00405957
Volume
51
Issue
4
Year of publication
1996
Pages
444 - 448
Database
ISI
SICI code
0040-5957(1996)51:4<444:MFDDIA>2.0.ZU;2-C
Abstract
The availability of new drugs for Alzheimer's disease, with different pharmacological profiles, leads to a redefinition the relevant methodo logy for developing drugs in this indication, including the inclusion/ exclusion criteria, the duration of the studies, and therefore, the re levant guidelines. This nas the purpose of the Giens Round-table devot ed to the new methodology for drug development in Alzheimer disease.